{"id":"dpyd","name":"DPYD","symbol":"DPYD","route":"/targets/dpyd/","asOf":"2026-09-23","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3012","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188641","uniprot":"https://www.uniprot.org/uniprotkb/Q12882/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q12882","open-targets":"https://platform.opentargets.org/target/ENSG00000188641","civic":"https://civicdb.org/genes/1806/summary","oncokb":"https://www.oncokb.org/gene/DPYD","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DPYD","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=DPYD","depmap":"https://depmap.org/portal/gene/DPYD?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000188641-DPYD","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/1806","omim":"https://www.omim.org/entry/612779"}],"products":[{"id":"folfoxiri","name":"FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan)","status":"established","modality":"Cytotoxic regimen","route":"/drugs/folfoxiri/"}],"trials":[{"id":"cairo5","name":"CAIRO5","nct":"NCT02162563","phase":"3","status":"mixed"},{"id":"tribe2","name":"TRIBE2","nct":"NCT02339116","phase":"3","status":"positive"},{"id":"tribe","name":"TRIBE","nct":"NCT00719797","phase":"3","status":"positive"},{"id":"nct05427669","name":"Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)","nct":"NCT05427669","phase":"3","status":"planned"},{"id":"nct07472868","name":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk","nct":"NCT07472868","phase":"3","status":"planned"},{"id":"nct05201430","name":"Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer","nct":"NCT05201430","phase":"3","status":"recruiting"},{"id":"nct05008809","name":"Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)","nct":"NCT05008809","phase":"3","status":"recruiting"},{"id":"nct06899477","name":"Pre-Operative Treatment in REseCTable COlon CanceR","nct":"NCT06899477","phase":"3","status":"planned"},{"id":"nct03671252","name":"Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Co","nct":"NCT03671252","phase":"3","status":"recruiting"},{"id":"nct07229846","name":"A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatme","nct":"NCT07229846","phase":"2","status":"planned"},{"id":"nct06242418","name":"CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)","nct":"NCT06242418","phase":"2","status":"recruiting"},{"id":"nct07817888","name":"mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer","nct":"NCT07817888","phase":"2","status":"planned"},{"id":"nct05571644","name":"Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer","nct":"NCT05571644","phase":"2","status":"recruiting"}],"pathways":[],"companies":[],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}